UBS Group’s Prothena PRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-40,000
Closed -$1.46M – 10784
2022
Q1
$1.46M Buy
+40,000
New +$1.44M ﹤0.01% 3741
2015
Q3
– Sell
-42,400
Closed -$2.23M – 8578
2015
Q2
$2.23M Buy
+42,400
New +$1.67M ﹤0.01% 2864
2015
Q1
– Sell
-500
Closed -$10K – 9238
2014
Q4
$10K Buy
+500
New +$10.4K ﹤0.01% 8395

Other funds holding PRTA

UBS Group's PRTA Position: Q3 2026 in Review

UBS Group increased its Prothena (PRTA) stake by 13% in Q3 2026, buying an estimated $277K and bringing the position to 272,478 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #4894.

UBS Group first reported a position in PRTA in Q4 2014 and has held it in 48 quarters since. The position peaked at $5.52M in Q3 2021. 182 funds tracked by Wall St. Rank hold PRTA as of Q3 2026.

  • UBS Group held 272,478 shares of Prothena worth $2.28M as of Q3 2026.
  • UBS Group bought 31,053 Prothena shares in Q3 2026, an estimated $277K.
  • Prothena made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4894 holding.
  • UBS Group first reported a position in Prothena in Q4 2014 and has held it in 48 quarters since.
  • UBS Group's Prothena position peaked at $5.52M in Q3 2021.
  • 182 funds tracked by Wall St. Rank held Prothena as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.